HIVVFHCSNCT02454569
Vicente Ferrer HIV Cohort Study
An observational study of HIV and Tuberculosis, run by Rural Development Trust Hospital at 1 site in India.
Trial summary
The VFHCS is a long-term prospective cohort study of HIV infected patients from a resource-poor rural setting in India. The aim of the study is to use data collected from routine clinical care in order to describe the epidemiology of HIV and its related conditions in the investigators area, and to study the… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- HIV, Tuberculosis, Cryptococcosis
- How many people
- 30,000 participants
- Where
- 1 siteIndia
- Study dates
- Sep 2009to Jan 2040
- How long will I take part?
- 30 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: HIV infected patients
Who may be able to join
- Positive serology for HIV
Who cannot join
- Refuse to consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Gerardo Alvarez-Uria contact
India1 site, 1 recruiting
- Recruiting
RDT Hospital
Battalapalli, Andhra Pradesh, 515661
Gerardo Alvarez Uria, MD PhD, hivbtp@gmail.com
Gerardo Alvarez-Uria
About this study
The VFHCS is a long-term prospective cohort study of HIV infected patients from a resource-poor rural setting in India. The aim of the study is to use data collected from routine clinical care in order to describe the epidemiology of HIV and its related conditions in the investigators area, and to study the effectiveness of health interventions in a "real-world" setting (implementation and operational research).
Read the detailed description
Andhra Pradesh is the state with highest burden of HIV in India. Anantapur is a district situated in the South border of Andhra Pradesh with 72% rural population and adult literacy rate of 74.1% in men and 54.3% in women. In Anantapur, the HIV epidemic is largely driven by heterosexual transmission and it is characterized by poor socioeconomic conditions and high levels of illiteracy.
Rural Development Trust (RDT) is a nongovernmental organization, which provides medical care to people living with HIV free of charge, including medicines, consultation and admission charges. In Bathalapalli Hospital, outpatient clinics and 71 beds are allocated exclusively for HIV or tuberculosis infected patients.
The Vicente Ferrer HIV Cohort Study (VFHCS) is a prospective open cohort study of all HIV infected patients who have attended Bathalapalli RDT Hospital. Routine clinical data from patients are collected prospectively since September 2009 and entered in a SQL-server database using C# as front end. Details of route of transmission, HIV associated risk factors and socio-demographic data are collected at enrolment. Data collected include medical treatment (antiretroviral treatment and other medications), laboratory investigations (haemogram, renal function tests, liver function tests, CD4 lymphocyte count, bacterial infections), and standardized diagnoses.
The objective of the VFHCS is to describe social and medical aspects related to HIV in the investigators setting, including:
- Epidemiology: trends in HIV incidence, transmission mechanisms, socioeconomic risk factors associated with HIV.
- Incidence and prevalence of opportunistic infections, especially tuberculosis and cryptococcosis.
- Life expectancy and factors associated with mortality
- Describe the retention across the continuum of care and investigate factors associated with loss to follow-up.
- Toxicity and effectiveness of antiretroviral therapy.
- Effectiveness of programmes to prevent mother to child transmission.
- Incidence and prevalence of non-communicable diseases such as cancer or cardiovascular diseases.
- Medical subject headings
- Tuberculosis, Cryptococcosis, Opportunistic Infections, Noncommunicable Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Survival since diagnosis of HIV infection
Measured: Time to event methods will be used. Participants will be followed from HIV diagnosis until death, assessed up to 30 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2015 (estimated)
- Study startSep 2009
- Primary completionSep 2039 (estimated)
- Study completionJan 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (32)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30,000 participants (estimated)
- Target duration
- 30 Years
Sponsor and investigators
- Lead sponsor
- Rural Development Trust Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gerardo Alvarez-Uria, Rural Development Trust Hospital
- Investigators
- Gerardo Alvarez-Uria, Principal investigator, Rural Development Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02454569
- Sponsor's protocol ID
- VFHCS
- Acronym
- VFHCS
- Status last verified
- Mar 2023
- First submitted
- 15 May 2015
- Last updated
- 29 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
Publications
Alvarez-Uria G, Midde M, Pakam R, Naik PK. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infect Dis Rep. 2012 Feb 17;4(1):e19. doi: 10.4081/idr.2012.e19. eCollection 2012 Jan 2.
PubMed 24470926Alvarez-Uria G, Naik PK, Pakam R, Midde M. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting. Trop Med Int Health. 2012 Sep;17(9):1152-5. doi: 10.1111/j.1365-3156.2012.02982.x. Epub 2012 Apr 5.
PubMed 22487689Alvarez-Uria G, Midde M, Pakam R, Kannan S, Bachu L, Naik PK. Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in India. Interdiscip Perspect Infect Dis. 2012;2012:293795. doi: 10.1155/2012/293795. Epub 2012 Apr 24.
PubMed 22611389Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK. Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. ISRN Pediatr. 2012;2012:763591. doi: 10.5402/2012/763591. Epub 2012 Jun 3.
PubMed 22701801Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group. An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20.
PubMed 27330070Alvarez-Uria G, Midde M, Naik PK. Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting. PeerJ. 2016 May 17;4:e2053. doi: 10.7717/peerj.2053. eCollection 2016.
PubMed 27231666Alvarez-Uria G, Midde M, Pakam R, Yalla PS, Naik PK, Reddy R. Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis. J Trop Med. 2015;2015:864271. doi: 10.1155/2015/864271. Epub 2015 Sep 10.
PubMed 26448766Alvarez-Uria G, Pakam R, Midde M, Yalla PS, Naik PK. Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients. Interdiscip Perspect Infect Dis. 2015;2015:535134. doi: 10.1155/2015/535134. Epub 2015 Aug 4.
PubMed 26347376Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014 Dec 9;17(1):19251. doi: 10.7448/IAS.17.1.19251. eCollection 2014.
PubMed 25499123Alvarez-Uria G, Pakam R, Naik PK, Midde M. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older. PLoS One. 2014 Sep 18;9(9):e108063. doi: 10.1371/journal.pone.0108063. eCollection 2014.
PubMed 25232730Alvarez-Uria G, Midde M, Pakam R, Naik PK. Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients. Biomed Res Int. 2014;2014:937817. doi: 10.1155/2014/937817. Epub 2014 Jun 11.
PubMed 25013814Alvarez-Uria G, Naik PK, Midde M, Pakam R. Mortality and Loss to Follow up Before Initiation of Antiretroviral Therapy Among HIV-Infected Children Eligible for HIV Treatment. Infect Dis Rep. 2014 May 13;6(2):5167. doi: 10.4081/idr.2014.5167. eCollection 2014 May 13.
PubMed 25002959Alvarez-Uria G. Description of the cascade of care and factors associated with attrition before and after initiating antiretroviral therapy of HIV infected children in a cohort study in India. PeerJ. 2014 Mar 13;2:e304. doi: 10.7717/peerj.304. eCollection 2014.
PubMed 24688879Alvarez-Uria G, Naik PK, Midde M, Pakam R. Predictors of loss to follow-up after engagement in care of HIV-infected children ineligible for antiretroviral therapy in an HIV cohort study in India. Germs. 2014 Mar 3;4(1):9-15. doi: 10.11599/germs.2014.1049. eCollection 2014 Mar.
PubMed 24639956Alvarez-Uria G, Pakam R, Midde M, Naik PK. Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines. Int Sch Res Notices. 2014 Dec 15;2014:704980. doi: 10.1155/2014/704980. eCollection 2014.
PubMed 27433510
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vicente Ferrer HIV Cohort Study
- ClinicalTrials.gov ID
- NCT02454569
- Acronym / sponsor ID
- VFHCS / VFHCS
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30,000 participants (estimated)
- Lead sponsor
- Rural Development Trust HospitalUniversity, hospital or other
- Study start
- Sep 2009
- Primary completion
- Sep 2039 (estimated)
- Study completion
- Jan 2040 (estimated)
- First posted
- 27 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The VFHCS is a long-term prospective cohort study of HIV infected patients from a resource-poor rural setting in India. The aim of the study is to use data collected from routine clinical care in order to describe the epidemiology of HIV and its related conditions in the investigators area, and to study the effectiveness of health interventions in a "real-world" setting (implementation and operational research).
Detailed description
Andhra Pradesh is the state with highest burden of HIV in India. Anantapur is a district situated in the South border of Andhra Pradesh with 72% rural population and adult literacy rate of 74.1% in men and 54.3% in women. In Anantapur, the HIV epidemic is largely driven by heterosexual transmission and it is characterized by poor socioeconomic conditions and high levels of illiteracy.
Rural Development Trust (RDT) is a nongovernmental organization, which provides medical care to people living with HIV free of charge, including medicines, consultation and admission charges. In Bathalapalli Hospital, outpatient clinics and 71 beds are allocated exclusively for HIV or tuberculosis infected patients.
The Vicente Ferrer HIV Cohort Study (VFHCS) is a prospective open cohort study of all HIV infected patients who have attended Bathalapalli RDT Hospital. Routine clinical data from patients are collected prospectively since September 2009 and entered in a SQL-server database using C# as front end. Details of route of transmission, HIV associated risk factors and socio-demographic data are collected at enrolment. Data collected include medical treatment (antiretroviral treatment and other medications), laboratory investigations (haemogram, renal function tests, liver function tests, CD4 lymphocyte count, bacterial infections), and standardized diagnoses.
The objective of the VFHCS is to describe social and medical aspects related to HIV in the investigators setting, including:
- Epidemiology: trends in HIV incidence, transmission mechanisms, socioeconomic risk factors associated with HIV.
- Incidence and prevalence of opportunistic infections, especially tuberculosis and cryptococcosis.
- Life expectancy and factors associated with mortality
- Describe the retention across the continuum of care and investigate factors associated with loss to follow-up.
- Toxicity and effectiveness of antiretroviral therapy.
- Effectiveness of programmes to prevent mother to child transmission.
- Incidence and prevalence of non-communicable diseases such as cancer or cardiovascular diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 30 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- HIV infected patients
Key inclusion criteria (1 listed)
- Positive serology for HIV
Key exclusion criteria (1 listed)
- Refuse to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality
Time frame: Time to event methods will be used. Participants will be followed from HIV diagnosis until death, assessed up to 30 years
Survival since diagnosis of HIV infection
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2023.
- Results publication: PubMed 24470926Alvarez-Uria G, Midde M, Pakam R, Naik PK. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infect Dis Rep. 2012 Feb 17;4(1):e19. doi: 10.4081/idr.2012.e19. eCollection 2012 Jan 2.
- Results publication: PubMed 22487689Alvarez-Uria G, Naik PK, Pakam R, Midde M. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting. Trop Med Int Health. 2012 Sep;17(9):1152-5. doi: 10.1111/j.1365-3156.2012.02982.x. Epub 2012 Apr 5.
- Results publication: PubMed 22611389Alvarez-Uria G, Midde M, Pakam R, Kannan S, Bachu L, Naik PK. Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in India. Interdiscip Perspect Infect Dis. 2012;2012:293795. doi: 10.1155/2012/293795. Epub 2012 Apr 24.
- Results publication: PubMed 22701801Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK. Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. ISRN Pediatr. 2012;2012:763591. doi: 10.5402/2012/763591. Epub 2012 Jun 3.
- Results publication: PubMed 27330070Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group. An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20.
- Results publication: PubMed 27231666Alvarez-Uria G, Midde M, Naik PK. Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting. PeerJ. 2016 May 17;4:e2053. doi: 10.7717/peerj.2053. eCollection 2016.
- Results publication: PubMed 26448766Alvarez-Uria G, Midde M, Pakam R, Yalla PS, Naik PK, Reddy R. Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis. J Trop Med. 2015;2015:864271. doi: 10.1155/2015/864271. Epub 2015 Sep 10.
- Results publication: PubMed 26347376Alvarez-Uria G, Pakam R, Midde M, Yalla PS, Naik PK. Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients. Interdiscip Perspect Infect Dis. 2015;2015:535134. doi: 10.1155/2015/535134. Epub 2015 Aug 4.
- Results publication: PubMed 25499123Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014 Dec 9;17(1):19251. doi: 10.7448/IAS.17.1.19251. eCollection 2014.
- Results publication: PubMed 25232730Alvarez-Uria G, Pakam R, Naik PK, Midde M. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older. PLoS One. 2014 Sep 18;9(9):e108063. doi: 10.1371/journal.pone.0108063. eCollection 2014.
- Results publication: PubMed 25013814Alvarez-Uria G, Midde M, Pakam R, Naik PK. Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients. Biomed Res Int. 2014;2014:937817. doi: 10.1155/2014/937817. Epub 2014 Jun 11.
- Results publication: PubMed 25002959Alvarez-Uria G, Naik PK, Midde M, Pakam R. Mortality and Loss to Follow up Before Initiation of Antiretroviral Therapy Among HIV-Infected Children Eligible for HIV Treatment. Infect Dis Rep. 2014 May 13;6(2):5167. doi: 10.4081/idr.2014.5167. eCollection 2014 May 13.
Related trials for HIV
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingObservational study
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
HIV
Not yet recruiting
Supporting Health and Empowerment Through Contingency Management and Affect Regulation
HIV Risk
RecruitingPhase 1
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Plasmablastic Lymphoma, HIV
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gerardo Alvarez-Uria contact
Gerardo Alvarez-Uria principal investigator
Rural Development Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV and Tuberculosis, run by Rural Development Trust Hospital at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gerardo Alvarez-Uria (hivbtp@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Time to event methods will be used. Participants will be followed from HIV diagnosis until death, assessed up to 30 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02454569, which also lists 32 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.